Hyperglycemia associated with protease inhibitors in an urban HIV- infected minority patient population

Annals of Pharmacotherapy

Volumn 34, Issue 5, 2000, Pages 580-584

  Dever, Lisa L ^a,b   Oruwari, Patrick A ^b,c   Figueroa, Wanda E ^a,b   O'Donovan, Carmel A ^a   Eng, Robert H K ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c Internal Medicine   (United States)

Author keywords

HIV infection; Hyperglycemia; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INDINAVIR; INSULIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; MALE; MINORITY GROUP; PRIORITY JOURNAL; RISK FACTOR; URBAN POPULATION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERGLYCEMIA; INDINAVIR; MALE; MIDDLE AGED; MINORITY GROUPS; RETROSPECTIVE STUDIES; RISK FACTORS; RITONAVIR; SAQUINAVIR; URBAN POPULATION;

EID: 0034059569     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19231     Document Type: Article

References (23)

1. Carpenter CJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277:1962-9.
2. Decks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-53.
3. Kopp JB, Miller KD, Mican JAM, Feuerstein IM, Vaughan E, Baker C, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127:119-25.
4. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus. FDA Public Health Advisory 1997.
5. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997;350:713-4.
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
7. Williamson DF. Descriptive epidemiology of body weight and weight change in US adults. Ann Intern Med 1993;119:646-9.
8. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-97.
9. Mann M, Koller E, Murgo A, Malozowski S, Bascanyi J, Leinung M. Glucocorticoidlike activity of megestrol: a summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997;157:1651-6.
10. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In: National Diabetes Data Group, eds. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health, 1995 (publication no. 95-1468):47-84.
11. Bell DS. Alcohol and the NIDDM patient. Diabetes Care 1996;19:509-12.
12. Giugliano D. Morphine, opioid peptides, and pancreatic cell function. Diabetes Care 1984;7:92-8.
13. Marian R, Hamman RF. Risk factors for non-insulin-dependent diabetes. In: National Diabetes Data Group, eds. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health, 1995 (publication no. 95-1468):179-220.
14. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337: 725-32.
15. Stone VE, Mauch MY, Steger K, Janas SF, Craven DE. Race, gender, drug use, and participation in AIDS clinical trials: lessons from a municipal hospital cohort. J Gen Intern Med 1997;12:150-7.
16. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999:353:2093-9.
17. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J. et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999;25:225-32.
18. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-73.
19. Yanovski JA, Miller KD, Kino T, Friedman TC, Chrousos GP, Tsigos C, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999;84:1925-31.
20. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.
21. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999;21:209-16.
22. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. Hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993;76:1423-7.
23. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998: 12:F37-9.